Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.44 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.44 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.44 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.44 |
| ▸ | P2RY6 | Q15077 | 7/20 | 0.42 |
| ▸ | P2RY2 | P41231 | 9/20 | 0.38 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.38 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14946340 | 1.00 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL14929243 | 0.89 | P2RY6 (0.40) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL14946318 | 0.89 | P2RY6 (0.40) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL14511255 | 0.89 | P2RY6 (0.40) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL14702151 | 0.89 | P2RY6 (0.40) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL10293413 | 0.89 | SLC28A1 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL2157176 | 0.88 | SLC28A1 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL5558240 | 0.88 | SLC28A1 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL13978164 | 0.88 | SLC28A1 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL14929468 | 0.88 | SLC28A1 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170056528-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNATX, INC. | 2017-03-02 | — | — | US | disclosed |
| US-9428535-B2 | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof | MODERNA THERAPEUTICS, INC. (US) | 2016-08-30 | — | — | US | disclosed |
| US-20130115272-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170056528-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | SLC28A1 80/4885SLC28A2 66/4885SLC29A1 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.